Any current/future new fundraising through debt or equity?

The company does not envisage any further dilution or equity fundraising going forward, as current revenue and projected PAT generation should suffice for funding needs. (Page 12) There is no plan to raise additional debt either; working capital is expected to be managed internally through PAT generation and existing bank overdraft/credit facilities (120 crore OD available but largely unutilized). (Page 7) Current capex is being funded through existing cash balances and rights issue proceeds; payments are staged based on project progress to optimize cash flow. (Page 7) Overall, no new fundr

Any current/future capex/capital investment/strategic investment?

Bhilwara HFO plant: Capex of around INR 200 crore (pure plant and machinery) as per government MOU; total capex likely around INR 400 crore. Commissioning targeted by October 2026. R-32 manufacturing facility: 10,000 metric ton capacity coming online; expected to start production by October, contributing significantly to revenue in FY27. Mumbattu facility expansion: Scaled up to a 12-tank facility to cover next 10 years; operational by August. Khalapur helium plant: Near completion, expected to start operations soon. HFO manufacturing plant: Planned post stabilization of Bhilwara plant, likely

Future growth expectations in sales/revenue/volumes?

Stallion India Fluorochemicals targets a revenue growth CAGR of 30-35% over the next three years. Current turnover is around INR 430 crores with a PAT of INR 40 crores. With the R-32 plant becoming fully operational, turnover is expected to cross INR 1100-1200 crores, with PAT around INR 180 crores. The HFO plant becoming operational will further boost revenues and profits. The company expects continuous expansion with one project stabilizing before starting the next. Long-term target by 2030 is INR 3000 crore revenue and INR 500 crore PAT. Demand for refrigerants and air-condition

Future growth expectations in earnings/operating earnings/profits/EPS?

Target revenue by 2030: INR 3,000 crore with PAT of INR 500 crore. Current turnover: INR 430 crore and INR 40 crore PAT. With full operation of R-32 facility, turnover expected to cross INR 1,100-1,200 crore with ~INR 180 crore PAT. HFO plant commencement to further boost revenues and profits post stabilization. Projected 30-35% CAGR revenue growth over the next 3-4 years supported by new plants and expansions. FY27 PAT expected around INR 100 crore with margins improving in H2 as manufacturing ramps up. Continuous sequential project commissioning planned every 6 months to ensure steady earnin

IN US

Sale is live|00:00:00left today

Stallion India Fluorochemicals LtdQ1 FY26Chemicals & Petrochemicals

Stallion India Fluorochemicals Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹182P/E: 37.3Market Cap: ₹1.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Stallion India Fluorochemicals targets a revenue growth CAGR of 30-35% over the next three years.
→Current turnover is around INR 430 crores with a PAT of INR 40 crores.
→With the R-32 plant becoming fully operational, turnover is expected to cross INR 1100-1200 crores, with PAT around INR 180 crores.
→The HFO plant becoming operational will further boost revenues and profits.
→The company expects continuous expansion with one project stabilizing before starting the next.
→Long-term target by 2030 is INR 3000 crore revenue and INR 500 crore PAT.
→Demand for refrigerants and air-conditioning in India is expected to grow 10-15% annually for the next 10 years.
→The semiconductor industry is a promising growth driver, with commercial contribution anticipated once helium facility starts (expected June).
→Market expansion is focused both domestically and in exports given global capacity deficits.

Margin guidance

Category 2

→Target revenue by 2030: INR 3,000 crore with PAT of INR 500 crore.
→Current turnover: INR 430 crore and INR 40 crore PAT.
→With full operation of R-32 facility, turnover expected to cross INR 1,100-1,200 crore with ~INR 180 crore PAT.
→HFO plant commencement to further boost revenues and profits post stabilization.
→Projected 30-35% CAGR revenue growth over the next 3-4 years supported by new plants and expansions.
→FY27 PAT expected around INR 100 crore with margins improving in H2 as manufacturing ramps up.
→Continuous sequential project commissioning planned every 6 months to ensure steady earnings growth.
→Specialty gases and semiconductor industry exposure expected to contribute significantly in long term.
→Margin improvement of 3-4% targeted alongside revenue growth due to product mix and operational efficiencies.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company does not envisage any further dilution or equity fundraising going forward, as current revenue and projected PAT generation should suffice for funding needs. (Page 12)
→There is no plan to raise additional debt either; working capital is expected to be managed internally through PAT generation and existing bank overdraft/credit facilities (120 crore OD available but largely unutilized). (Page 7)
→Current capex is being funded through existing cash balances and rights issue proceeds; payments are staged based on project progress to optimize cash flow. (Page 7)
→Overall, no new fundraising through debt or equity is anticipated beyond the existing measures, given the company's conservative financial management and growth plans. (Pages 7, 12)

Order book

The transcript does not specifically mention current or expected order book or pending orders in detail. However, key points related to orders and capex include: - Orders for most equipment (tank manufacturers, pumps) have already been placed with 20-30% advance payments; balance payments are scheduled upon delivery and commissioning. - Capex utilization appears low currently due to payment stagger but will accelerate as materials arrive by June. - No explicit mention of outstanding orders or order book value was provided. - The company expects strong internal PAT generation and has access to a Rs 120 crore overdraft facility if needed, indicating financial flexibility to support order execution. - They have not entered into pre-contracts for R-32 sales yet, preferring to avoid price-detrimental agreements before production starts. - Focus remains on ramping up production and converting capacities into sales rather than discussing pending order book specifics.

Capex plans

Yes

→Bhilwara HFO plant: Capex of around INR 200 crore (pure plant and machinery) as per government MOU; total capex likely around INR 400 crore. Commissioning targeted by October 2026.
→R-32 manufacturing facility: 10,000 metric ton capacity coming online; expected to start production by October, contributing significantly to revenue in FY27.
→Mumbattu facility expansion: Scaled up to a 12-tank facility to cover next 10 years; operational by August.
→Khalapur helium plant: Near completion, expected to start operations soon.
→HFO manufacturing plant: Planned post stabilization of Bhilwara plant, likely after mid-2027; capex range previously mentioned as INR 250 crore in current year and INR 500+ crore next year—conservative estimates.
→Continuous expansion approach: One project at a time, stabilization before next, aiming for sustained growth over next 5-7 years.
→No further dilution or fundraise expected beyond current capex; internal PAT generation expected to fund working capital requirements.

How does Stallion India Fluorochemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Stallion India Fluorochemicals Ltd

Rev 2Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Stallion India Fluorochemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio